The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. During the last U10 grant cycle we increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to explore the utility of molecular prognostication with the correlation of specific genes with outcomes of therapy;(b) to investigate novel strategies of chemotherapy for common solid tumors in cancer patients, with a particular emphasis on minority populations and the elderly;(c) to develop novel strategies of prevention of GU and Gl cancers. Thus, USC investigators have contributed extensively to SWOG trials and administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Activities have included (a) administrative and scientific leadership (Vice Chairs of GU Committee and Gl Committee;cadre membership in Breast, Melanoma and Committee for Women/Special Populations;Scientific Advisory Board;External Advisory Boards of EORTC and Cancer Research UK;Data and Safety Monitoring Committee of SWOG;core labs for pharmacology and molecular prognostication studies of GU and Gl Committees);(b) mentoring through the Young Investigator Program with 2 Young Investigator Awards;(c) scientific research agendas translated from USC to SWOG including circulating tumor cells in SWOG prostate clinical trials, a NCI funded R01 to identify molecular markers for patients enrolled in SWOG 9304 and developed two prospecitve clinical trials to establish molecular markers in gastric and colon cancer (d) continuing high levels of clinical trial accrual with majority of cases from USC (e) development of a Minority Recruitment Strategies which is integrated into the overall strategy of the Norris Comprehensive Cancer Center, has resulted in the provision of a broad range of clinical and translational trials for minority populations leading to a continued improvement in access to clinical trials, particularly for Latino population groups (f) Increase the leadership of USC to improve cancer chemotherapy among the elderly, another under-served population group.
Through funding the USC/Norris Comprehensive Cancer Center will be able to provide significant translational research data and projects which will impact the design and development of clinical trials within SWOG. This grant will allow to continue our efforts in improving cancer chemotherapy to minority and ederly population we serve in Los Angeles County.
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64|
|Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8|
|Bohanes, Pierre; Rankin, Cathryn J; Blanke, Charles D et al. (2015) Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res 21:1583-90|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
Showing the most recent 10 out of 134 publications